Mission/Purpose: The mission of the Tumor Tissue Core Laboratory is to facilitate translational cancer research by collecting and supplying high quality, well annotated human tissues (neoplastic and normal) to CCCWFU investigators. The Tumor Tissue Core carries out this mission by maintaining a repository of patient-derived tumors and matched normal tissues that are accompanied by pertinent clinical information, and by providing a Web-based database of available tumor and normal tissues for investigators to examine. Additionally, the Tumor Tissue Core assists investigators with custom collection of fresh human tissue samples for prospective translational research projects. The Tumor Tissue Core collaborates with the Cancer Biomedical Informatics Grid (caBIG?) initiative to link the core with other such repositories, nationally. Assets: The Tumor Tissue Core maintains a Web-based database for interaction of investigators with Core personnel and access to banked tissue inventories, as well as a functional instance linked to the caBIG? grid. The Tumor Tissue Core Laboratory is based in a fully functional research laboratory located on the 4th floor of the Hanes Building for processing tumor tissue samples. Presently, the Core maintains four -80?C freezers. Additionally, the Core has access to a Hacker motor-driven cryostat (maintained by the Cellular Imaging Core), an Agilent BioAnalyzer for RNA quality analysis (maintained by the MicroArray Core) and an Arcturus Pixcell ll/Olympus laser capture microscope for tissue microdissection (maintained by the Cellular Imaging Core). Usage: In the last year the Tumor Tissue Core collected 5354 tissue vials for research purposes. 1019 tissue vials were disbursed for 22 research projects. 88% of the disbursed tissue vials were utilized by CCCWFU members. The Tumor Tissue Core presently has over 22,000 tissue vials from >7000 patients, provided by 44 institutional surgeons. We have a comprehensive quality control protocol for monitoring sample quality. Future Directions: In the next funding cycle, the capabilities and utilization of the Tumor Tissue Core will be expanded by: (1) adding the caTIES and caARRAY modules that provide improved tissue annotation to the caTISSUE suite that is already grid enabled at our Cancer Center;(2) offering pilot fund RFA's to bolster the utilization of banked tissues;(3) increasing specimen utilization by the cancer genomics program that is part of the CCCWFU strategic plan;and (4) Adding a bar code scanner mechanism for more timely entry of collected sample information.

Public Health Relevance

This Shared Resource provides an adequate supply of high quality human tissue with appropriate annotation that is easily accessible by Cancer Center investigators. Successful grant applications and individual projects require a concerted effort by surgeons, pathologists, clinicians, basic scientists, and technicians to collect and maintain a biorepository that adheres to the best practices of human tissue collection. The Shared Resource at Wake Forest University School of Medicine has made it a priority to provide this service to its members.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA012197-39
Application #
8617229
Study Section
Subcommittee B - Comprehensiveness (NCI)
Project Start
Project End
Budget Start
2014-02-01
Budget End
2015-01-31
Support Year
39
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Wake Forest University Health Sciences
Department
Type
DUNS #
City
Winston-Salem
State
NC
Country
United States
Zip Code
27157
Yang, M; Forbes, M E; Bitting, R L et al. (2018) Incorporating blood-based liquid biopsy information into cancer staging: time for a TNMB system? Ann Oncol 29:311-323
Godwin, Ryan C; Gmeiner, William H; Salsbury Jr, Freddie R (2018) All-atom molecular dynamics comparison of disease-associated zinc fingers. J Biomol Struct Dyn 36:2581-2594
Votanopoulos, Konstantinos Ioannis; Bartlett, David; Moran, Brendan et al. (2018) PCI is Not Predictive of Survival After Complete CRS/HIPEC in Peritoneal Dissemination from High-Grade Appendiceal Primaries. Ann Surg Oncol 25:674-678
Lamar, Zanetta S; Dothard, Andrew; Kennedy, LeAnne et al. (2018) Hyperglycemia during first-line R-CHOP or dose adjusted R-EPOCH chemotherapy for non-Hodgkin lymphoma is prevalent and associated with chemotherapy alteration - a retrospective study. Leuk Lymphoma 59:1871-1877
Melvin, Ryan L; Xiao, Jiajie; Berenhaut, Kenneth S et al. (2018) Using correlated motions to determine sufficient sampling times for molecular dynamics. Phys Rev E 98:023307
Bhatt, Nikunj B; Pandya, Darpan N; Dezarn, William A et al. (2018) Practical Guidelines for Cerenkov Luminescence Imaging with Clinically Relevant Isotopes. Methods Mol Biol 1790:197-208
Gesell, Sabina B; Golden, Shannon L; Limkakeng Jr, Alexander T et al. (2018) Implementation of the HEART Pathway: Using the Consolidated Framework for Implementation Research. Crit Pathw Cardiol 17:191-200
Mao, Chengqiong; Qu, Ping; Miley, Michael J et al. (2018) P-glycoprotein targeted photodynamic therapy of chemoresistant tumors using recombinant Fab fragment conjugates. Biomater Sci 6:3063-3074
Bhatt, Nikunj B; Pandya, Darpan N; Rideout-Danner, Stephanie et al. (2018) A comprehensively revised strategy that improves the specific activity and long-term stability of clinically relevant 89Zr-immuno-PET agents. Dalton Trans 47:13214-13221
Andrews, Rachel N; Caudell, David L; Metheny-Barlow, Linda J et al. (2018) Fibronectin Produced by Cerebral Endothelial and Vascular Smooth Muscle Cells Contributes to Perivascular Extracellular Matrix in Late-Delayed Radiation-Induced Brain Injury. Radiat Res 190:361-373

Showing the most recent 10 out of 548 publications